Barclays raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $95 from $80 and keeps an Overweight rating on the shares. The company reported a second consecutive beat quarter for Tryngolza and raised 2025 revenue guidance, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals: Strong Q3 Performance and Promising Pipeline Drive Buy Rating
- Ionis Pharmaceuticals Reports Strong Q3 2025 Growth
- Ionis Pharmaceuticals Shines in Q3 2025 Earnings Call
- Ionis Pharmaceuticals: Strong Growth Potential and Strategic Advancements Drive Buy Rating
- Ionis Pharmaceuticals: A Compelling Buy with Strong Performance and Promising Growth Catalysts